The expression of long non coding RNA genes is associated with expression with polymorphisms of HULC rs7763881 and MALAT1 rs619586 in hepatocellular carcinoma and HBV Egyptian patients

Motawi, Tarek K.; El-Maraghy, Shohda A.; Sabry, Dina; Mehana, Noha Ali

doi:10.1002/jcb.28726

Cited by 29 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, a number of studies have reported the association of lncRNA HULC polymorphisms with decreased risk of HCC, ESCC, and CRC. [24][25][26][27] In this casecontrol study, we first investigated the association between HULC rs7763881 SNP and GC risk but did not observe a significant association between them. However, stratified analysis by age, gender, tumor differentiation, histological type, LNM, T classification, and tumor stage revealed statistically significant association between HULC rs7763881 CC genotype and increased GC risk of the undifferentiated, diffuse-type, LNM-positive, T3/T4, and tumor stage III groups.…”

Section: Discussionmentioning

confidence: 99%

“…Till date, contradictory to our results, previous studies have reported the relationship between rs7763881 AC or AC+CC genotype with the decreased risk of several cancers, including HBV carried HCC, ESCC, and CRC. [24][25][26][27] Through stratification analysis. Of Chinese populations, Kang between HOTAIR overexpression and poor differentiation, LNM, and advanced tumor stage (III-IV).…”

Section: Discussionmentioning

confidence: 99%

“…25 In Egyptian populations, Shaker et al reported the association between HULC rs7763881 SNP and decreased colorectal cancer (CRC) risk, 27 and Motawi et al reported the association between HULC rs7763881 SNP and decreased HCC risk. 26 However, the association between HULC rs7763881 SNP and GC risk is not yet reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Association Between lncRNA HULC rs7763881 Polymorphism and Gastric Cancer Risk</p>

Hong¹,

Jin²,

Chang³

et al. 2020

PGPM

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common cancers in the world. Recently, several studies have suggested that single-nucleotide polymorphisms (SNPs) of long noncoding RNA (lncRNA) are associated with GC risk. However, the association of the lncRNA highly upregulated in liver cancer (HULC) SNP with GC risk is not yet known. The aims of this study were to evaluate the association between HULC rs7763881 SNP and the risk of GC and GC subgroups via a case-control study. Patients and Methods: rs7763881 was genotyped using TaqMan genotyping assay with 459 GC patients and 379 controls. Results: A significant association between HULC rs7763881 SNP and GC risk was not found. However, after adjustment for age and gender, the rs7763881 recessive model (CC) showed a significant association with an increased GC risk in the undifferentiated (odds ratio (OR) = 1.85, 95% confidence interval (CI) = 1.17-2.94, P = 0.009), diffuse-type GC (OR = 1.72, 95% CI = 1.05-2.82, P = 0.033), LNM-positive (OR = 2.02, 95% CI = 1.24-3.27, P = 0.004), T3/T4 (OR = 1.75, 95% CI = 1.05-2.91, P = 0.032), and tumor stage III (OR = 2.01, 95% CI = 1.17-3.45, P = 0.011) subgroups when compared to the rs7763881 combined genotypes (AA+AC). Furthermore, after adjusting for age and gender, the rs7763881 additive model (CC) indicated a significantly higher GC risk than rs7763881 AA genotype in the undifferentiated (OR = 1.96, 95% CI = 1.15-3.32, P = 0.013), diffuse-type GC (OR = 2.08, 95% CI = 1.23-3.52, P = 0.004), and LNM-positive (OR = 2.00, 95% CI = 1.14-3.49, P = 0.016) subgroups. Conclusion: Our findings suggest that the HULC rs7763881 SNP is associated with increased susceptibility to GC. However, further studies are required to validate our results in large populations as well as different ethnic groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Association Between lncRNA HULC rs7763881 Polymorphism and Gastric Cancer Risk</p>

Hong¹,

Jin²,

Chang³

et al. 2020

PGPM

View full text Add to dashboard Cite

show abstract

“…Based on the selection criteria, 12 studies [17][18][19][20][21][25][26][27][28][29][30][31] were included in this meta-analysis ( Fig. 1).…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

Association Between LncRNA MALAT1 Polymorphisms and Cancer Risk: A Meta-Analysis Based on7007 Cases and 8791 Controls

Rong

Cheng

2020

Preprint

View full text Add to dashboard Cite

Background: LncRNA metastasis associated with lung adenocarcinoma transcript-1 (MALAT1) was involved in pathogenesis and progress of diverse cancers. To investigate the association of MALAT1 and cancer susceptibility, this meta-analysis was appraised.Methods: 12 studies including 7007 cancer patients and 8791 controls were selected for this meta-analysis. Ratio radiation (ORS) and 95% confidence interval (CIS) were used to assess cancer susceptibility.Results: There was no significant association between rs3200401 polymorphism and the risk of cancer. However, rs3200401 was correlated with an increased risk of digestive cancer in allelic model (OR=1.15, 95%CI=1.04-1.28, P=0.009) and dominant model (OR=1.16, 95%CI=1.02-1.31, P=0.02). There was a borderline association between rs664589 and cancer susceptibility under the dominant model (OR=1.17, 95%CI=1.00-1.38, P=0.05). Rs619586 was associated with decreased cancer risk in all populations under four models (G vs A: OR=0.86, 95%CI=0.78-0.94, P=0.001; GG vs AA: OR=0.60, 95%CI=0.42-0.84, P=0.003; GG+AG vs AA: OR=0.87, 95%CI=0.78-0.97, P=0.009; GG vs AG+AA: OR=0.61, 95%CI=0.44-0.84, P=0.003). Moreover, rs1194338 was decreased associated with cancer susceptibility (A vs C: OR=0.89, 95%CI=0.80-0.98, P=0.01; AA vs CC: OR=0.77, 95%CI=0.62-0.96, P=0.02; AA+AC vs CC: OR=0.87, 95%CI=0.77-1.00, P=0.04; AA vs AC+CC: OR=0.82, 95%CI=0.67-1.00, P=0.05).Conclusion: Our results suggest that rs619586 and rs1194338 are associated with decreased cancer risk, while rs3200401 and rs664589 correlated with increased digestive cancer risk.

show abstract

“…Recent advancements in high-throughput gene sequencing analysis have led to the identification of a large number of differentially expressed long non-coding RNAs (lncRNAs) in the progression of various cancers (Jing et al, 2018;Li et al, 2018;Malih, Saidijam & Malih, 2016). A growing number of studies have reported that dysregulated lncRNAs in HCC are related to chronic HBV or HCV infection, histological type, TNM stage, lymph node metastasis, and prognosis Motawi et al, 2019;Zheng et al, 2017). Closely related dysregulated lncRNAs may assist in identifying valuable biomarkers for the diagnosis and prognosis of HCC.…”

Section: Introductionmentioning

confidence: 99%

Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma

Zhang

Yang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is an aggressive cancer with a poor prognosis and a high incidence. The molecular changes and novel biomarkers of HCC need to be identified to improve the diagnosis and prognosis of this disease. We investigated the current research concentrations of HCC and identified the transcriptomics-related biomarkers of HCC from The Cancer Genome Atlas (TGCA) database. Methods We investigated the current research concentrations of HCC using literature metrology analysis for studies conducted from 2008 to 2018. We identified long noncoding RNAs (lncRNAs) that correlated with the clinical features and survival prognoses of HCC from The Cancer Genome Atlas (TGCA) database. Differentially expressed genes (lncRNAs, miRNAs, and mRNAs) were also identified by TCGA datasets in HCC tumor tissues. A lncRNA competitive endogenous RNA (ceRNA) network was constructed from lncRNAs based on intersected lncRNAs. Survival times and the association between the expression levels of the key lncRNAs of the ceRNA network and the clinicopathological characteristics of HCC patients were analyzed using TCGA. Real-time polymerase chain reaction (qRT-PCR) was used to validate the reliability of the results in tissue samples from 20 newly-diagnosed HCC patients. Results Analysis of the literature pertaining to HCC research revealed that current research is focused on lncRNA functions in tumorigenesis and tumor development. A total of 128 HCC dysregulated lncRNAs were identified; 66 were included in the co-expressed ceRNA network. We analyzed survival times and the associations between the expression of 66 key lncRNAs and the clinicopathological features of the HCC patients identified from TCGA. Twenty-six lncRNAs were associated with clinical features of HCC (P < 0.05) and six key lncRNAs were associated with survival time (log-rank test P < 0.05). Six key lncRNAs were selected for the validation of their expression levels in 20 patients with newly diagnosed HCC using qRT-PCR. Consistent fold changes in the trends of up and down regulation between qRT-PCR validation and TCGA proved the reliability of our bioinformatics analysis. Conclusions We used integrative bioinformatics analysis of the TCGA datasets to improve our understanding of the regulatory mechanisms involved with the functional features of lncRNAs in HCC. The results revealed that lncRNAs are potential diagnostic and prognostic biomarkers of HCC.

show abstract

The expression of long non coding RNA genes is associated with expression with polymorphisms of HULC rs7763881 and MALAT1 rs619586 in hepatocellular carcinoma and HBV Egyptian patients

Cited by 29 publications

References 30 publications

<p>Association Between lncRNA HULC rs7763881 Polymorphism and Gastric Cancer Risk</p>

<p>Association Between lncRNA HULC rs7763881 Polymorphism and Gastric Cancer Risk</p>

Association Between LncRNA MALAT1 Polymorphisms and Cancer Risk: A Meta-Analysis Based on7007 Cases and 8791 Controls

Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma

Contact Info

Product

Resources

About